PT-141 for Libido: Nearly 6 in 10 Responded in Trials

PT-141 for Libido: Nearly 6 in 10 Responded in Trials

Bremelanotide, sold under the brand name VYLEESI, can increase sexual desire in premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), and phase 3 trials back that effect with statistically significant results. The FDA has approved it specifically for this group, not for men or postmenopausal women, and prescribing it well means screening for side effects like nausea before a patient ever self-injects.

TL;DR:

• A screening should quantify desire and distress, check blood pressure and cardiovascular history, and rule out medication effects, depression, thyroid dysfunction, or pregnancy.
• Across the phase 3 trials, about 58% to 59% of treated participants met responder criteria, compared with 36% to 40% receiving placebo.
• Inject 1.75 mg into the abdomen or thigh at least 45 minutes before sex; do not exceed one dose daily or eight per month.
• Nausea affects 4 in 10 patients; uncontrolled hypertension or cardiovascular disease rules out treatment, and skin darkening or no benefit after eight weeks warrants review.

Table of Contents

• What PT-141 (Bremelanotide) Is and How It Works
• Clinical Evidence: RECONNECT Phase 3 Trials and What the Data Show
• Who Is an Appropriate Candidate for PT-141 Therapy
• Dose, Administration, and What to Expect Day to Day
• Managing Side Effects and Staying Safe on Therapy
• How We Evaluate and Deliver Peptide Therapy for Low Desire
• Setting Realistic Expectations for PT-141 Therapy
• Getting Evaluated for Low Libido at evoyouthful
• FAQ
• Sources

What PT-141 (Bremelanotide) Is and How It Works

PT-141 is the research name for bremelanotide, a peptide that acts on melanocortin receptors in the brain rather than on blood flow to the genitals. Where many libido treatments target the body’s plumbing, this one targets the signaling pathways tied to sexual motivation itself, which is part of why its effects and its side effect profile look different from other options on the market.

Reviewers describe bremelanotide as a centrally acting melanocortin receptor agonist, distinguishing its approach from medications that work through vascular or hormonal routes, as outlined in a peer-reviewed mechanistic review. The marketed product, VYLEESI, comes as a single-use autoinjector delivering a 1.75 mg subcutaneous dose, designed for a patient to administer at home ahead of anticipated sexual activity.

It helps to understand how this compares with other tools clinicians use for low desire:

• Bremelanotide (VYLEESI): acts centrally on melanocortin receptors to influence desire signaling in the brain, taken as needed.
• Testosterone or BHRT: addresses hormonal deficits that can suppress libido, typically used for ongoing hormonal imbalance rather than as a situational dose. We discuss this approach further on our BHRT page.
• PDE5 inhibitors: improve blood flow to support physical arousal and erectile function, which is a different problem than a lack of desire itself.

Each of these tools solves a distinct piece of sexual health, which is why an accurate diagnosis matters before choosing one.

Clinical Evidence: RECONNECT Phase 3 Trials and What the Data Show

The core evidence behind bremelanotide comes from the RECONNECT program: two identical phase 3 randomized controlled trials enrolling roughly 1,200 premenopausal women with acquired, generalized HSDD, according to the published trial data. Participants self-administered the drug as needed before sexual activity rather than on a fixed schedule, which mirrors how it’s prescribed in practice today.

Nearly 6 in 10 treated participants responded to bremelanotide, compared to roughly a third to two-fifths on placebo, according to integrated responder analyses from the RECONNECT trials. These responder rates were built on two primary outcome measures:

• FSFI-Desire domain: scores improved significantly for women on bremelanotide compared with placebo, reflecting a measurable increase in sexual desire.
• FSDS-DAO item 13: distress related to low desire decreased significantly more in the treatment group, which matters because distress is part of the clinical definition of HSDD.
• Responder analyses: combined results across both trials showed roughly 58 to 59% of treated women meeting responder criteria, against roughly 36 to 40% on placebo.

Adverse events told a parallel story. Nausea was the most common complaint, flushing and headache followed, and a minority of participants discontinued early because of these effects, a pattern confirmed in both the trial publications and the drug’s labeling. None of this makes bremelanotide a universal fix, but it does give clinicians a clear evidence base for who is likely to benefit and what to warn them about beforehand.

Who Is an Appropriate Candidate for PT-141 Therapy

The FDA approved bremelanotide for one specific population: premenopausal women with acquired, generalized HSDD, meaning the drop in desire developed after a period of normal desire and isn’t limited to one partner or situation, according to the FDA’s approval announcement. It’s not indicated for men or for postmenopausal women, and that limitation shapes every screening conversation we have with a prospective patient.

A thorough clinical assessment typically works through these steps:

1. Sexual and relationship history: understanding when the change in desire began and whether it’s situational or generalized.
2. Validated questionnaires: tools like the FSFI and FSDS help quantify desire and distress rather than relying on a vague self-report.
3. Medication and psychiatric review: many medications, including some antidepressants, can suppress desire and need to be ruled out or addressed first.
4. Cardiovascular risk assessment: blood pressure and cardiovascular history matter because bremelanotide can cause transient changes in both.

When a reversible cause surfaces, such as a hormonal imbalance or a medication side effect, we often prefer to address that directly, sometimes alongside counseling resources like the ones described in this overview of sex therapy for couples, rather than starting a peptide first.

Pro Tip: Ask your clinician to rule out thyroid dysfunction, depression, and medication side effects before assuming low desire needs a pharmacologic fix.

Dose, Administration, and What to Expect Day to Day

The labeled dose is straightforward: 1.75 mg delivered subcutaneously into the abdomen or thigh using the autoinjector, timed at least 45 minutes before anticipated sexual activity, according to the FDA prescribing information. The label caps use at one dose per 24 hours and advises against more than 8 doses per month, and it recommends discontinuing treatment after 8 weeks if a patient sees no improvement.

Practical details matter for first-time users:

• Injection site rotation: alternating between abdomen and thigh reduces local irritation over repeated use.
• Storage: autoinjectors are kept at room temperature and used before the labeled expiration, following the manufacturer’s handling instructions.
• What follows injection: many patients notice transient flushing or mild nausea in the hour after dosing, which is why timing around a meal can help.
• Drug interactions: bremelanotide can slow gastric emptying and meaningfully reduce absorption of oral naltrexone, a combination we flag during medication review.

Pregnancy should be ruled out or actively prevented during use, since bremelanotide isn’t studied for safety in pregnancy, and patients using hormonal contraception should mention it during screening.

Managing Side Effects and Staying Safe on Therapy

Most patients tolerate bremelanotide, but the side effect profile is real enough that it shapes how we counsel every new patient. Roughly 4 in 10 patients report nausea, according to the FDA label, and it tends to ease after the first couple of doses rather than persisting indefinitely. Flushing affects around 1 in 5 patients, and headache occurs in roughly 1 in 10.

Beyond the common complaints, a few safety signals deserve attention:

• Blood pressure and heart rate: dosing can cause a transient rise in blood pressure alongside a drop in heart rate, which is why uncontrolled hypertension and cardiovascular disease are contraindications.
• Focal hyperpigmentation: a small percentage of patients, around 1%, develop darkened patches of skin, most often on the face, gums, or breasts, and this risk rises with cumulative dosing.
• When to stop: new or worsening skin pigmentation, persistent high blood pressure readings, or lack of benefit after 8 weeks are all reasons to reassess rather than continue indefinitely.

Nausea management is often the deciding factor in whether a patient sticks with treatment, so planning for it upfront, rather than reacting after the fact, tends to produce better outcomes.

How We Evaluate and Deliver Peptide Therapy for Low Desire

Our intake for anyone exploring peptide therapy starts with a full medical history, validated questionnaires like the FSFI and FSDS, a blood pressure and cardiovascular check, and a review of every medication a patient is taking. When pregnancy is a possibility, we test before moving forward.

From there, the workflow is hands-on rather than a prescription handed across a desk:

• Patient education: we walk through what the data actually shows, including realistic responder rates, before a patient decides this is right for them.
• Autoinjector training: patients practice the technique with us and demonstrate it back before using it independently at home.
• Anti-emetic planning: for patients prone to nausea, we discuss short-term options to manage it through the first several doses.
• Follow-up and tracking: we schedule a reassessment to review symptom changes and decide together whether to continue.

Pro Tip: Bring a list of every medication and supplement you take to your first screening visit, since several common prescriptions can interact with bremelanotide or explain low desire on their own.

Setting Realistic Expectations for PT-141 Therapy

In practice, the benefit from bremelanotide tends to be real but modest, and it varies a lot from one patient to the next. Before starting, we ask patients to name what success would look like for them, because “more desire” means different things to different people, and that clarity shapes how we judge whether treatment is working.

Most patients and clinicians reassess around the 8-week mark. Early nausea is common and usually temporary, but it’s worth naming upfront so it doesn’t derail a trial of therapy that might otherwise work. Shared decision-making, not a one-size prescription, is what makes this approach sustainable.

— Elizabeth Vogstrom, PA-C

Getting Evaluated for Low Libido at evoyouthful

A real answer to low desire starts with a proper evaluation, not guesswork, and that’s exactly what a consultation with us provides: medical screening, a personalized plan, and hands-on injection training if bremelanotide or another peptide fits your situation.

Here’s what a visit with us typically includes:

• A full screening that covers sexual history, cardiovascular risk, and medication review.
• A personalized plan that may include peptide therapy alongside hormone testing if indicated.
• Direct training on self-administration so you feel confident before using anything at home.

If low desire has been affecting your relationship or confidence, book a consultation through our peptide therapy page and let’s figure out what’s actually going on.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

What is the best peptide for low libido?

Bremelanotide (VYLEESI) is the only peptide with FDA approval specifically for low sexual desire, and that approval is limited to premenopausal women with acquired, generalized HSDD. Other peptides are sometimes discussed for sexual health, but they don’t carry the same regulatory backing or trial evidence bremelanotide has.

Can testosterone injections improve libido?

Testosterone and broader bioidentical hormone replacement therapy can improve libido when low desire is driven by a hormonal deficiency, which is a different mechanism than bremelanotide’s central nervous system approach. We cover how hormone testing factors into this decision on our BHRT for men page.

How does PT-141 work on men?

PT-141 is not FDA-approved for men, and the labeling for VYLEESI applies specifically to premenopausal women with HSDD. Men experiencing low desire are typically better served starting with a hormonal and medical evaluation, since testosterone deficiency is a common and treatable contributor.

How much PT-141 to take?

The labeled dose is 1.75 mg delivered subcutaneously via autoinjector, taken at least 45 minutes before anticipated sexual activity. Dosing is limited to once every 24 hours, and the prescribing information advises against using it more than 8 times per month.

What are the most common side effects of PT-141?

Nausea is the most frequently reported side effect, affecting roughly 4 in 10 patients, followed by flushing and headache. These effects are documented in the FDA label and tend to lessen after the first few doses.

Sources

• RECONNECT phase 3 trials: Bremelanotide for HSDD (PubMed)
• VYLEESI (bremelanotide) DailyMed / FDA prescribing information

Recommended

• Confirm Low T Before BHRT For Men: Guideline Steps and Risks
• Evidence First: Andropause Symptoms and Treatment for Men, Sex Gains
• Testosterone for Retirees: What Trials Show on Performance
• BHRT for Men | Low Testosterone Treatment in Wayzata, MN